Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AHCC in HPV-positive HNSCC
NCT06693323Phase 2
Key facts
- Status
- Recruiting
- Start
- Dec 2024
- Primary completion
- Dec 2027
- Countries
- 1
- Sponsor
- University of California, Irvine
- Modality
- Botanical Extract, Nutraceutical
- Conditions
- head and neck squamous cell carcinoma (HNSCC)
01
Overview
Phase 2, open-label trial of active hexose correlated compound in head and neck squamous cell carcinoma (HNSCC), sponsored by University of California, Irvine. Primary endpoint: Overall Survival at 60 months. Started Dec 2024; status: recruiting.
02
Design
- Study design
- Non-randomizedOpen-labelSingle group
03
Who it enrols
Patients aged 18-79 with pathologically proven HPV-positive HNSCC, post-surgery with high-risk features (positive margins or ENE), M0 stage, and ECOG 0-1.
04
Endpoints
Primary
Overall Survival
Beyond the preview
Go deeper on NCT06693323.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06693323.